Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

322 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CXCR4 and hif-1α as prognostic molecular markers for stage 3 colon cancer patients: post hoc analysis of the randomized, multicenter phase 3 PETACC-2 trial dataset.
Maderer A, Fiteni F, Tanis E, Mauer M, Schmitt T, Aust DE, Lutz MP, Roelofson F, Gog C, Weinmann A, Koehne CH, Moehler M, Thomaidis T. Maderer A, et al. Among authors: mauer m. Acta Oncol. 2021 Nov;60(11):1543-1547. doi: 10.1080/0284186X.2021.1959057. Epub 2021 Aug 6. Acta Oncol. 2021. PMID: 34355650 Clinical Trial. No abstract available.
Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.
Tanis E, Julié C, Emile JF, Mauer M, Nordlinger B, Aust D, Roth A, Lutz MP, Gruenberger T, Wrba F, Sorbye H, Bechstein W, Schlag P, Fisseler A, Ruers T. Tanis E, et al. Among authors: mauer m. Eur J Cancer. 2015 Nov;51(17):2708-17. doi: 10.1016/j.ejca.2015.08.014. Epub 2015 Sep 2. Eur J Cancer. 2015. PMID: 26342674 Clinical Trial.
Immunotherapy in gastrointestinal cancer: Recent results, current studies and future perspectives.
Moehler M, Delic M, Goepfert K, Aust D, Grabsch HI, Halama N, Heinrich B, Julie C, Lordick F, Lutz MP, Mauer M, Alsina Maqueda M, Schild H, Schimanski CC, Wagner AD, Roth A, Ducreux M. Moehler M, et al. Among authors: mauer m. Eur J Cancer. 2016 May;59:160-170. doi: 10.1016/j.ejca.2016.02.020. Epub 2016 Mar 31. Eur J Cancer. 2016. PMID: 27039171 Free article. Review.
Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG.
Kataoka K, Kinoshita T, Moehler M, Mauer M, Shitara K, Wagner AD, Schrauwen S, Yoshikawa T, Roviello F, Tokunaga M, Boku N, Ducreux M, Terashima M, Lordick F; EORTC GITCG Group and JCOG SCGC Group. Kataoka K, et al. Among authors: mauer m. Gastric Cancer. 2017 Sep;20(5):904-912. doi: 10.1007/s10120-017-0696-7. Epub 2017 Feb 1. Gastric Cancer. 2017. PMID: 28150070
Lapatinib with ECF/X in the first-line treatment of metastatic gastric cancer according to HER2neu and EGFR status: a randomized placebo-controlled phase II study (EORTC 40071).
Moehler M, Schad A, Maderer A, Atasoy A, Mauer ME, Caballero C, Thomaidis T, John JMM, Lang I, Van Cutsem E, Freire J, Lutz MP, Roth A; EORTC Gastrointestinal Tract Cancer Group. Moehler M, et al. Among authors: mauer me. Cancer Chemother Pharmacol. 2018 Oct;82(4):733-739. doi: 10.1007/s00280-018-3667-8. Epub 2018 Aug 13. Cancer Chemother Pharmacol. 2018. PMID: 30105460 Clinical Trial.
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, Kang YK, Rha SY, Cats A, Tokunaga M, Lordick F. Wagner AD, et al. Among authors: mauer m. BMC Cancer. 2019 May 24;19(1):494. doi: 10.1186/s12885-019-5675-4. BMC Cancer. 2019. PMID: 31126258 Free PMC article. Clinical Trial.
VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study.
Smyth E, Knödler M, Giraut A, Mauer M, Nilsson M, Van Grieken N, Wagner AD, Moehler M, Lordick F. Smyth E, et al. Among authors: mauer m. Front Oncol. 2020 Jan 30;9:1320. doi: 10.3389/fonc.2019.01320. eCollection 2019. Front Oncol. 2020. PMID: 32083013 Free PMC article.
Pre- and Postoperative Capecitabine Without or With Oxaliplatin in Locally Advanced Rectal Cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD.
Schmoll HJ, Stein A, Van Cutsem E, Price T, Hofheinz RD, Nordlinger B, Daisne JF, Janssens J, Brenner B, Reinel H, Hollerbach S, Caca K, Fauth F, Hannig CV, Zalcberg J, Tebbutt N, Mauer ME, Marreaud S, Lutz MP, Haustermans K. Schmoll HJ, et al. J Clin Oncol. 2021 Jan 1;39(1):17-29. doi: 10.1200/JCO.20.01740. Epub 2020 Oct 1. J Clin Oncol. 2021. PMID: 33001764 Clinical Trial.
322 results